A detailed history of Swisspartners Ltd. transactions in Context Therapeutics Inc. stock. As of the latest transaction made, Swisspartners Ltd. holds 180,000 shares of CNTX stock, worth $198,000. This represents 0.15% of its overall portfolio holdings.

Number of Shares
180,000
Previous 85,000 111.76%
Holding current value
$198,000
Previous $94,000 24.47%
% of portfolio
0.15%
Previous 0.1%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

BUY
$0.61 - $1.42 $57,950 - $134,900
95,000 Added 111.76%
180,000 $117,000
Q3 2022

Nov 01, 2022

BUY
$1.11 - $2.08 $47,469 - $88,951
42,765 Added 101.25%
85,000 $94,000
Q1 2022

May 11, 2022

BUY
$1.72 - $2.82 $48,022 - $78,734
27,920 Added 195.04%
42,235 $92,000
Q1 2022

May 04, 2022

SELL
$1.72 - $2.82 $48,022 - $78,734
-27,920 Reduced 66.11%
14,315 $4.98 Million
Q4 2021

Feb 09, 2022

BUY
$2.66 - $7.45 $112,345 - $314,650
42,235 New
42,235 $114,000

Others Institutions Holding CNTX

About Context Therapeutics Inc.


  • Ticker CNTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 15,966,100
  • Market Cap $17.6M
  • Description
  • Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therape...
More about CNTX
Track This Portfolio

Track Swisspartners Ltd. Portfolio

Follow Swisspartners Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Swisspartners Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Swisspartners Ltd. with notifications on news.